Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer

Clinical trial NCT02606305 · COMPLETED

Trial details

NCT number: NCT02606305
Sponsor: ImmunoGen, Inc.
Status: COMPLETED
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Epithelial Ovarian Cancer Primary Peritoneal Cancer Fallopian Tube Cancer

Start date: 2016-03-02
Primary completion: 2021-03-12
Enrollment: 264

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.